Conference attendance
Pharming Group announces presentations at CIS 2026 Annual Meeting, including leniolisib pediatric data in APDS and clinical experience in CVID and related disorders
Pharming Group N.V. today announced presentations at the 2026 Annual Meeting of the Clinical Immunology Society (CIS), taking place May 6-9 in New Orleans, LA.
Anurag Relan, Chief Medical Officer of Pharming, commented:
“We are pleased to present data at CIS that advance the understanding of APDS and other primary immunodeficiencies characterized by immune dysregulation. The clinical experience observations support the ongoing clinical trials evaluating leniolisib in CVID and CVID-like disorders, and we look forward to results in the second half of this year.”